시장보고서

상품코드

1624226

인간 마이크로바이옴 시장 규모 및 예측, 세계 및 지역 점유율, 동향, 성장 기회 분석 보고서 : 유형별, 용도별, 질환 유형별, 지역별

Human Microbiome Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type, Application, Disease Type, and Geography

발행일: 2024년 11월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 174 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

인간 마이크로바이옴 시장은 2023년 10억 7,000만 달러에서 2031년 48억 4,000만 달러에 달할 것으로 예상되며, 2023년부터 2031년까지 연평균 20.8%의 CAGR을 기록할 것으로 예상됩니다. 시장 성장을 촉진하는 주요 요인은 주요 시장 기업의 대규모 투자와 정부의 노력입니다. 또한, 정밀 의료의 출현은 예측 기간 동안 시장을 견인할 가능성이 높습니다. 그러나 상업화 과정의 어려움은 시장 저해요인으로 작용하고 있습니다.

인간 마이크로바이옴 산업의 성장, 혁신, 시장 역학은 시장의 주요 기업들의 투자에 크게 영향을 받습니다. 주요 기업들은 마이크로바이옴 기반의 새로운 프로바이오틱스, 진단 및 치료법을 개발하기 위해 연구개발에 많은 투자를 하고 있습니다. 이러한 투자는 기술 혁신을 촉진하고 새로운 균주, 작용기전, 의약학적 용도를 찾아내는 데 도움이 됩니다. 임상시험에 많은 자금이 투입되고 있으며, 이는 마이크로바이옴 기반 제품의 효능과 안전성을 입증하는 데 필수적입니다. 마이크로바이옴 매핑 기술의 선구자인 캔버스 바이오사이언시스(Canvas Biosciences)는 2023년 6월 1,200만 달러의 프리 시리즈 A 투자 유치를 발표했습니다. 캔버스 바이오사이언스가 독자적으로 개발한 플랫폼 기술은 마이크로바이옴 관련 질병에 대한 의약품 개발을 획기적으로 변화시킬 수 있는 잠재력을 가지고 있으며, 이번 투자를 통해 더욱 발전할 수 있을 것으로 기대됩니다. 이러한 파트너십은 자원과 노하우, 기술 발전의 공유를 용이하게 하고 제품 개발을 가속화할 수 있습니다. 예를 들어, 2023년 7월, 세계 최대 음료 및 식품 회사인 네슬레와 SFI 최고 수준의 연구 센터인 APC 마이크로바이옴 아일랜드와의 새로운 공동연구가 발표되었습니다. 이 공동연구는 인간 마이크로바이옴의 다양한 측면에 초점을 맞추고 인간의 건강과 웰빙을 향상시키는 신제품 개발을 지원할 예정입니다. 마이크로바이옴 분석에 투자하는 기업은 120여 개에 달하며, 수많은 스타트업이 이 분야에 뛰어들고 있습니다. 플래그십 파이오니어링, 세벤투르 파트너스, 바이오 가이아가 가장 적극적인 투자자로 꼽힙니다. 이처럼 주요 기업들의 투자 증가는 시장 성장을 촉진할 가능성이 높습니다.

경쟁사 비교 분석에서는 제품 포트폴리오(제품 만족도, 제품 특징, 가용성), 최근 시장 동향(인수합병, 신제품 출시 및 강화, 투자 및 자금 조달, 수상, 계약, 제휴 및 협력, 인지도, 확장), 지역적 입지를 기반으로 경쟁 상황을 더 잘 이해하고 의사결정을 내리는 데 도움이 될 것입니다. 인간 마이크로바이옴 시장을 평가하고 분류하고 있습니다. 이 보고서는 세계 인간 마이크로바이옴 시장의 주요 업체들의 최근 주요 동향과 혁신에 대해 심층적으로 조사했습니다. 주요 시장 기업으로는 MaaT Pharma, & Ferring Holdings SA, & Finch Therapeutics Group Inc, & AOBiome Therapeutics Inc., & Seres Therapeutics Inc, & Merck & Co Inc. Yakult Honsha Co., Ltd, & Rebiotix, & Inc, & IFF Nutrition & Biosciences, & and Synthetic Biologics, Inc. 등이 있습니다.

인간 마이크로바이옴 시장은 제품 유형과 소프트웨어 서비스 유형으로 나뉩니다. 제품 부문은 2023년 인간 마이크로바이옴 시장에서 더 큰 점유율을 차지하고 있으며, 2023년부터 2031년까지 더 높은 CAGR을 기록할 것으로 예상됩니다. 인체 마이크로바이옴은 인체 내 및 인체에 존재하는 모든 미생물을 포함합니다. 이러한 미생물은 질병 관리에 활용될 수 있는 잠재력을 가지고 있습니다. 마이크로바이옴 제품은 심각한 증상의 치료와 개인별 맞춤치료에 유망한 것으로 평가받고 있습니다. 마이크로바이옴은 신경질환, 염증성 질환, 암과 관련이 있습니다.

2023년 인간 마이크로바이옴 시장은 용도에 따라 치료, 진단, 연구로 구분되며, 치료제 분야가 2023년 가장 큰 비중을 차지하고 있습니다. 장내 미생물의 중요한 대사적 잠재력과 인간 건강 유지에 대한 역할은 인간 질병에 대처하기 위한 치료제로 활용될 수 있는 새로운 가능성과 함께 등장하고 있습니다. 최근 몇 년 동안 마이크로바이옴 조절제라고도 불리는 마이크로바이옴 기반 치료제가 빠르게 발전하고 있습니다. 몇 가지 유망한 후보물질이 임상 파이프라인을 진행하고 있습니다. 예를 들어, 2023년 4월 페링제약의 VOWST는 18세 이상 환자의 클로스트리디움 디피실(C. difficile) 감염 재발 예방에 대한 적응증으로 승인된 최초의 경구용 분변 미생물 제제입니다.

인간 마이크로바이옴 시장은 질병 유형별로 비만, 당뇨병, 자가면역질환, 암, 소화기 질환, 기타로 구분되며, 2023년 인간 마이크로바이옴 시장에서는 GIT 질환 분야가 가장 큰 비중을 차지하고 있습니다.

인간 마이크로바이옴 시장에서 사업을 전개하는 기업들은 다양한 유기적, 무기적 전략을 채택하고 있습니다. 유기적 전략에는 주로 제품 출시와 제품 승인이 포함됩니다. 시장에서 볼 수 있는 무기적 성장 전략은 인수, 제휴, 파트너십입니다. 이러한 성장 전략을 통해 시장 진입 기업은 사업을 확장하고, 지리적 입지를 강화하며, 전체 시장 성장에 기여할 수 있습니다. 또한, 인수 및 제휴와 같은 전략은 고객 기반을 강화하고 제품 포트폴리오를 확장하는 데 도움이 됩니다. 인간 마이크로바이옴 시장의 주요 업체들의 주요 발전은 다음과 같습니다.

2024년 3월, MaaT Pharma는 유럽에서 CHRONOS라는 후향적 다기관 임상시험을 시작한다고 발표했습니다. 이 시험의 목적은 MaaT013과 마이크로바이옴 중재를 받지 않은 환자들을 대상으로 3차 치료의 유효성 데이터를 제공하는 것입니다. 이 시험은 규제 당국의 요청에 의한 것이 아니며, 이미 자금이 확보되어 있어 자금 계획에는 영향을 미치지 않습니다.

2021년 7월, Seres Therapeutics, Inc.와 Nestle Health Science는 Seres의 경구용 마이크로바이옴 치료제 SER-109의 재발성 클로스트리디움 디피실(CDI) 감염에 대한 미국 및 캐나다에서의 공동 상업화를 위한 상업화 라이선스 계약을 체결하였습니다.

인간 마이크로바이옴 시장 - 주요 시장 역학
시장 성장 촉진요인
- 주요 시장 기업에 의한 거액의 투자
- 정부 이니셔티브
시장 성장 억제요인
- 상업화시 과제
시장 기회
- 연구개발에 대한 적극 투자
향후 동향
- 정밀의료의 출현
성장 촉진요인과 억제요인의 영향

제6장 인간 마이크로바이옴 시장 : 세계 시장 분석

인간 마이크로바이옴 시장 매출, 2021-2031년
인간 마이크로바이옴 시장 예측 분석

제7장 인간 마이크로바이옴 시장 분석 - 유형별

제품
소프트웨어와 서비스

제8장 인간 마이크로바이옴 시장 분석 - 용도별

치료
진단
조사

제9장 인간 마이크로바이옴 시장 분석 - 질환 유형별

비만
당뇨병
자가면역질환
암
소화기
기타

제10장 인간 마이크로바이옴 시장 - 지역별 분석

북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제11장 경쟁 구도

인간 마이크로바이옴 시장의 성장 전략
유기적 성장 전략
무기적 성장 전략

제12장 기업 개요

MaaT Pharma
Ferring Holdings SA
AOBiome Therapeutics Inc
Finch Therapeutics Group Inc
Seres Therapeutics Inc
Merck & Co Inc
Yakult Honsha Co., Ltd.
Rebiotix, Inc.
IFF Nutrition & Biosciences
Synthetic Biologics, Inc.

제13장 부록

ksm 25.02.03

The human microbiome market is expected to reach US$ 4.84 billion by 2031 from US$ 1.07 billion in 2023; the market is estimated to register a CAGR of 20.8% during 2023-2031. Major factors driving the market growth significant investments by key market players and government initiatives. Further, the emergence of precision medicine is likely to boost the market during the forecast period. However, challenges during commercialization are among the market deterrents.

The human microbiome industry's growth, innovation, and market dynamics are greatly influenced by the investments made by major players in the market. Major players are engaged in making significant investments in research and development to create novel probiotics, diagnostics, and treatments based on the microbiome. These expenditures stimulate innovation, identifying new strains, modes of action, and medicinal uses. Clinical trials receive a large amount of funding, which is essential for demonstrating the effectiveness and safety of products based on the microbiome. A pioneer in microbiome mapping technology, Kanvas Biosciences, announced a US$ 12 million Pre-Series A funding round in June 2023. The company's proprietary platform technology, which has the potential to transform drug development for illnesses linked to the microbiome, will be further developed with the help of the investment. These partnerships make sharing resources, know-how, and technological advancements easier, speeding up product development. For instance, a new collaboration was announced between the world's largest food and beverage company, Nestle, and a top-tier SFI research center, APC Microbiome Ireland, in July 2023. The collaboration centers on different aspects of the human microbiome and helps develop new products to enhance human health and wellness. As many as 120 companies are reportedly investing in microbiome analysis, and numerous startups are entering this field. Flagship Pioneering, Seventure Partners, and BioGaia are the most active investors. Thus, increase in investments by key players is likely drive the growth of market.

The comparative company analysis evaluates and categorizes the human microbiome market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global human microbiome market. The key market players are MaaT Pharma; Ferring Holdings SA; Finch Therapeutics Group Inc; AOBiome Therapeutics Inc.; Seres Therapeutics Inc; Merck & Co Inc; Yakult Honsha Co., Ltd; Rebiotix; Inc; IFF Nutrition & Biosciences; and Synthetic Biologics, Inc.

The human microbiome market, based on type, is segmented into product and software and services. The product segment held a larger share of the human microbiome market in 2023, and it is expected to register a higher CAGR during 2023-2031. The human microbiome includes all microorganisms in and on the human body. These microbes have potential for use in disease management. Microbiome products show promise in treating severe conditions and personalizing therapy. The microbiota has been linked to neurological diseases, inflammatory diseases, and cancer.

Based on application, the market is segmented into therapeutics, diagnostics, and research. The therapeutics segment accounted for the largest share of the human microbiome market in 2023. The significant metabolic potential of gut microbes and their role in maintaining human health is emerging, with new possibilities to utilize them as therapeutic agents for addressing human disorders. In recent years, microbiome-based therapeutics, also known as microbiome modulators, have made rapid advances. Several promising candidates have moved forward through the clinical pipeline. For instance, in April 2023, Ferring Pharmaceuticals' VOWST, the first fecal microbiota product taken orally, was approved for preventing recurrence of Clostridioides difficile (C. difficile) infection in patients 18 years and older, following antibiotic treatment for recurrent infection.

Based on disease type, the human microbiome market is segmented into obesity, diabetes, autoimmune disorders, cancer, GIT disorders, and others. The GIT disorders segment held the largest share of the human microbiome market in 2023.

Various organic and inorganic strategies are adopted by companies operating in the human microbiome market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the human microbiome market are listed below.

In March 2024, MaaT Pharma announced the launch of a retrospective multicenter trial called CHRONOS in Europe. Its objective is to provide the Company efficacy data for 3rd-line therapies for patients not receiving MaaT013 or any microbiome intervention. This study was not requested by regulatory authorities and does not impact cash projections as funding has already been secured.

In July 2021, Seres Therapeutics, Inc. and Nestle Health Science entered into commercialization license agreement to jointly commercialize SER-109, Seres' investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the United States (U.S.) and Canada.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Human Microbiome Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Human Microbiome Market - Key Market Dynamics

5.1 Human Microbiome Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Significant Investments by Key Market Players
- 5.2.2 Government Initiatives
5.3 Market Restraints
- 5.3.1 Challenges During Commercialization
5.4 Market Opportunities
- 5.4.1 Robust Investment in Research and Development
5.5 Future Trends
- 5.5.1 Emergence of Precision Medicine
5.6 Impact of Drivers and Restraints:

6. Human Microbiome Market - Global Market Analysis

6.1 Human Microbiome Market Revenue (US$ Million), 2021-2031
6.2 Human Microbiome Market Forecast Analysis

7. Human Microbiome Market Analysis - by Type

7.1 Product
- 7.1.1 Overview
- 7.1.2 Product: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Software and Services
- 7.2.1 Overview
- 7.2.2 Software and Services: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)

8. Human Microbiome Market Analysis - by Application

8.1 Therapeutics
- 8.1.1 Overview
- 8.1.2 Therapeutics: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Diagnostics
- 8.2.1 Overview
- 8.2.2 Diagnostics: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Research
- 8.3.1 Overview
- 8.3.2 Research: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)

9. Human Microbiome Market Analysis - by Disease Type

9.1 Obesity
- 9.1.1 Overview
- 9.1.2 Obesity: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Diabetes
- 9.2.1 Overview
- 9.2.2 Diabetes: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Autoimmune Disorder
- 9.3.1 Overview
- 9.3.2 Autoimmune Disorder: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
9.4 Cancer
- 9.4.1 Overview
- 9.4.2 Cancer: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
9.5 GIT
- 9.5.1 Overview
- 9.5.2 GIT: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)

10. Human Microbiome Market - Geographical Analysis

10.1 Overview
10.2 North America
- 10.2.1 North America Human Microbiome Market Overview
- 10.2.2 North America: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
- 10.2.3 North America: Human Microbiome Market Breakdown, by Type
  - 10.2.3.1 North America: Human Microbiome Market - Revenue and Forecast Analysis - by Type
- 10.2.4 North America: Human Microbiome Market Breakdown, by Product
  - 10.2.4.1 North America: Human Microbiome Market - Revenue and Forecast Analysis - by Product
- 10.2.5 North America: Human Microbiome Market Breakdown, by Application
  - 10.2.5.1 North America: Human Microbiome Market - Revenue and Forecast Analysis - by Application
- 10.2.6 North America: Human Microbiome Market Breakdown, by Disease Type
  - 10.2.6.1 North America: Human Microbiome Market - Revenue and Forecast Analysis - by Disease Type
- 10.2.7 North America: Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.2.7.1 North America: Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.2.7.2 United States: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.2.7.2.1 United States: Human Microbiome Market Breakdown, by Type
    - 10.2.7.2.2 United States: Human Microbiome Market Breakdown, by Product
    - 10.2.7.2.3 United States: Human Microbiome Market Breakdown, by Application
    - 10.2.7.2.4 United States: Human Microbiome Market Breakdown, by Disease Type
  - 10.2.7.3 Canada: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.2.7.3.1 Canada: Human Microbiome Market Breakdown, by Type
    - 10.2.7.3.2 Canada: Human Microbiome Market Breakdown, by Product
    - 10.2.7.3.3 Canada: Human Microbiome Market Breakdown, by Application
    - 10.2.7.3.4 Canada: Human Microbiome Market Breakdown, by Disease Type
  - 10.2.7.4 Mexico: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.2.7.4.1 Mexico: Human Microbiome Market Breakdown, by Type
    - 10.2.7.4.2 Mexico: Human Microbiome Market Breakdown, by Product
    - 10.2.7.4.3 Mexico: Human Microbiome Market Breakdown, by Application
    - 10.2.7.4.4 Mexico: Human Microbiome Market Breakdown, by Disease Type
10.3 Europe
- 10.3.1 Europe Human Microbiome Market Overview
- 10.3.2 Europe: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
- 10.3.3 Europe: Human Microbiome Market Breakdown, by Type
  - 10.3.3.1 Europe: Human Microbiome Market - Revenue and Forecast Analysis - by Type
- 10.3.4 Europe: Human Microbiome Market Breakdown, by Product
  - 10.3.4.1 Europe: Human Microbiome Market - Revenue and Forecast Analysis - by Product
- 10.3.5 Europe: Human Microbiome Market Breakdown, by Application
  - 10.3.5.1 Europe: Human Microbiome Market - Revenue and Forecast Analysis - by Application
- 10.3.6 Europe: Human Microbiome Market Breakdown, by Disease Type
  - 10.3.6.1 Europe: Human Microbiome Market - Revenue and Forecast Analysis - by Disease Type
- 10.3.7 Europe: Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.3.7.1 Europe: Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.3.7.2 United Kingdom: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.7.2.1 United Kingdom: Human Microbiome Market Breakdown, by Type
    - 10.3.7.2.2 United Kingdom: Human Microbiome Market Breakdown, by Product
    - 10.3.7.2.3 United Kingdom: Human Microbiome Market Breakdown, by Application
    - 10.3.7.2.4 United Kingdom: Human Microbiome Market Breakdown, by Disease Type
  - 10.3.7.3 Germany: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.7.3.1 Germany: Human Microbiome Market Breakdown, by Type
    - 10.3.7.3.2 Germany: Human Microbiome Market Breakdown, by Product
    - 10.3.7.3.3 Germany: Human Microbiome Market Breakdown, by Application
    - 10.3.7.3.4 Germany: Human Microbiome Market Breakdown, by Disease Type
  - 10.3.7.4 France: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.7.4.1 France: Human Microbiome Market Breakdown, by Type
    - 10.3.7.4.2 France: Human Microbiome Market Breakdown, by Product
    - 10.3.7.4.3 France: Human Microbiome Market Breakdown, by Application
    - 10.3.7.4.4 France: Human Microbiome Market Breakdown, by Disease Type
  - 10.3.7.5 Italy: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.7.5.1 Italy: Human Microbiome Market Breakdown, by Type
    - 10.3.7.5.2 Italy: Human Microbiome Market Breakdown, by Product
    - 10.3.7.5.3 Italy: Human Microbiome Market Breakdown, by Application
    - 10.3.7.5.4 Italy: Human Microbiome Market Breakdown, by Disease Type
  - 10.3.7.6 Spain: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.7.6.1 Spain: Human Microbiome Market Breakdown, by Type
    - 10.3.7.6.2 Spain: Human Microbiome Market Breakdown, by Product
    - 10.3.7.6.3 Spain: Human Microbiome Market Breakdown, by Application
    - 10.3.7.6.4 Spain: Human Microbiome Market Breakdown, by Disease Type
  - 10.3.7.7 Rest of Europe: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.3.7.7.1 Rest of Europe: Human Microbiome Market Breakdown, by Type
    - 10.3.7.7.2 Rest of Europe: Human Microbiome Market Breakdown, by Product
    - 10.3.7.7.3 Rest of Europe: Human Microbiome Market Breakdown, by Application
    - 10.3.7.7.4 Rest of Europe: Human Microbiome Market Breakdown, by Disease Type
10.4 Asia Pacific
- 10.4.1 Asia Pacific Human Microbiome Market Overview
- 10.4.2 Asia Pacific: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
- 10.4.3 Asia Pacific: Human Microbiome Market Breakdown, by Type
  - 10.4.3.1 Asia Pacific: Human Microbiome Market - Revenue and Forecast Analysis - by Type
- 10.4.4 Asia Pacific: Human Microbiome Market Breakdown, by Product
  - 10.4.4.1 Asia Pacific: Human Microbiome Market - Revenue and Forecast Analysis - by Product
- 10.4.5 Asia Pacific: Human Microbiome Market Breakdown, by Application
  - 10.4.5.1 Asia Pacific: Human Microbiome Market - Revenue and Forecast Analysis - by Application
- 10.4.6 Asia Pacific: Human Microbiome Market Breakdown, by Disease Type
  - 10.4.6.1 Asia Pacific: Human Microbiome Market - Revenue and Forecast Analysis - by Disease Type
- 10.4.7 Asia Pacific: Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.4.7.1 Asia Pacific: Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.4.7.2 China: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.7.2.1 China: Human Microbiome Market Breakdown, by Type
    - 10.4.7.2.2 China: Human Microbiome Market Breakdown, by Product
    - 10.4.7.2.3 China: Human Microbiome Market Breakdown, by Application
    - 10.4.7.2.4 China: Human Microbiome Market Breakdown, by Disease Type
  - 10.4.7.3 Japan: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.7.3.1 Japan: Human Microbiome Market Breakdown, by Type
    - 10.4.7.3.2 Japan: Human Microbiome Market Breakdown, by Product
    - 10.4.7.3.3 Japan: Human Microbiome Market Breakdown, by Application
    - 10.4.7.3.4 Japan: Human Microbiome Market Breakdown, by Disease Type
  - 10.4.7.4 India: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.7.4.1 India: Human Microbiome Market Breakdown, by Type
    - 10.4.7.4.2 India: Human Microbiome Market Breakdown, by Product
    - 10.4.7.4.3 India: Human Microbiome Market Breakdown, by Application
    - 10.4.7.4.4 India: Human Microbiome Market Breakdown, by Disease Type
  - 10.4.7.5 Australia: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.7.5.1 Australia: Human Microbiome Market Breakdown, by Type
    - 10.4.7.5.2 Australia: Human Microbiome Market Breakdown, by Product
    - 10.4.7.5.3 Australia: Human Microbiome Market Breakdown, by Application
    - 10.4.7.5.4 Australia: Human Microbiome Market Breakdown, by Disease Type
  - 10.4.7.6 South Korea: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.7.6.1 South Korea: Human Microbiome Market Breakdown, by Type
    - 10.4.7.6.2 South Korea: Human Microbiome Market Breakdown, by Product
    - 10.4.7.6.3 South Korea: Human Microbiome Market Breakdown, by Application
    - 10.4.7.6.4 South Korea: Human Microbiome Market Breakdown, by Disease Type
  - 10.4.7.7 Rest of APAC: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.4.7.7.1 Rest of APAC: Human Microbiome Market Breakdown, by Type
    - 10.4.7.7.2 Rest of APAC: Human Microbiome Market Breakdown, by Product
    - 10.4.7.7.3 Rest of APAC: Human Microbiome Market Breakdown, by Application
    - 10.4.7.7.4 Rest of APAC: Human Microbiome Market Breakdown, by Disease Type
10.5 Middle East and Africa
- 10.5.1 Middle East and Africa Human Microbiome Market Overview
- 10.5.2 Middle East and Africa: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
- 10.5.3 Middle East and Africa: Human Microbiome Market Breakdown, by Type
  - 10.5.3.1 Middle East and Africa: Human Microbiome Market - Revenue and Forecast Analysis - by Type
- 10.5.4 Middle East and Africa: Human Microbiome Market Breakdown, by Product
  - 10.5.4.1 Middle East and Africa: Human Microbiome Market - Revenue and Forecast Analysis - by Product
- 10.5.5 Middle East and Africa: Human Microbiome Market Breakdown, by Application
  - 10.5.5.1 Middle East and Africa: Human Microbiome Market - Revenue and Forecast Analysis - by Application
- 10.5.6 Middle East and Africa: Human Microbiome Market Breakdown, by Disease Type
  - 10.5.6.1 Middle East and Africa: Human Microbiome Market - Revenue and Forecast Analysis - by Disease Type
- 10.5.7 Middle East and Africa: Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.5.7.1 Middle East and Africa: Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.5.7.2 South Africa: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.7.2.1 South Africa: Human Microbiome Market Breakdown, by Type
    - 10.5.7.2.2 South Africa: Human Microbiome Market Breakdown, by Product
    - 10.5.7.2.3 South Africa: Human Microbiome Market Breakdown, by Application
    - 10.5.7.2.4 South Africa: Human Microbiome Market Breakdown, by Disease Type
  - 10.5.7.3 Saudi Arabia: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.7.3.1 Saudi Arabia: Human Microbiome Market Breakdown, by Type
    - 10.5.7.3.2 Saudi Arabia: Human Microbiome Market Breakdown, by Product
    - 10.5.7.3.3 Saudi Arabia: Human Microbiome Market Breakdown, by Application
    - 10.5.7.3.4 Saudi Arabia: Human Microbiome Market Breakdown, by Disease Type
  - 10.5.7.4 United Arab Emirates: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.7.4.1 United Arab Emirates: Human Microbiome Market Breakdown, by Type
    - 10.5.7.4.2 United Arab Emirates: Human Microbiome Market Breakdown, by Product
    - 10.5.7.4.3 United Arab Emirates: Human Microbiome Market Breakdown, by Application
    - 10.5.7.4.4 United Arab Emirates: Human Microbiome Market Breakdown, by Disease Type
  - 10.5.7.5 Rest of Middle East and Africa: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.5.7.5.1 Rest of Middle East and Africa: Human Microbiome Market Breakdown, by Type
    - 10.5.7.5.2 Rest of Middle East and Africa: Human Microbiome Market Breakdown, by Product
    - 10.5.7.5.3 Rest of Middle East and Africa: Human Microbiome Market Breakdown, by Application
    - 10.5.7.5.4 Rest of Middle East and Africa: Human Microbiome Market Breakdown, by Disease Type
10.6 South and Central America
- 10.6.1 South and Central America Human Microbiome Market Overview
- 10.6.2 South and Central America: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
- 10.6.3 South and Central America: Human Microbiome Market Breakdown, by Type
  - 10.6.3.1 South and Central America: Human Microbiome Market - Revenue and Forecast Analysis - by Type
- 10.6.4 South and Central America: Human Microbiome Market Breakdown, by Product
  - 10.6.4.1 South and Central America: Human Microbiome Market - Revenue and Forecast Analysis - by Product
- 10.6.5 South and Central America: Human Microbiome Market Breakdown, by Application
  - 10.6.5.1 South and Central America: Human Microbiome Market - Revenue and Forecast Analysis - by Application
- 10.6.6 South and Central America: Human Microbiome Market Breakdown, by Disease Type
  - 10.6.6.1 South and Central America: Human Microbiome Market - Revenue and Forecast Analysis - by Disease Type
- 10.6.7 South and Central America: Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.6.7.1 South and Central America: Human Microbiome Market - Revenue and Forecast Analysis - by Country
  - 10.6.7.2 Brazil: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.6.7.2.1 Brazil: Human Microbiome Market Breakdown, by Type
    - 10.6.7.2.2 Brazil: Human Microbiome Market Breakdown, by Product
    - 10.6.7.2.3 Brazil: Human Microbiome Market Breakdown, by Application
    - 10.6.7.2.4 Brazil: Human Microbiome Market Breakdown, by Disease Type
  - 10.6.7.3 Argentina: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.6.7.3.1 Argentina: Human Microbiome Market Breakdown, by Type
    - 10.6.7.3.2 Argentina: Human Microbiome Market Breakdown, by Product
    - 10.6.7.3.3 Argentina: Human Microbiome Market Breakdown, by Application
    - 10.6.7.3.4 Argentina: Human Microbiome Market Breakdown, by Disease Type
  - 10.6.7.4 Rest of South and Central America: Human Microbiome Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.6.7.4.1 Rest of South and Central America: Human Microbiome Market Breakdown, by Type
    - 10.6.7.4.2 Rest of South and Central America: Human Microbiome Market Breakdown, by Product
    - 10.6.7.4.3 Rest of South and Central America: Human Microbiome Market Breakdown, by Application
    - 10.6.7.4.4 Rest of South and Central America: Human Microbiome Market Breakdown, by Disease Type

11. Competitive Landscape

11.1 Overview
11.2 Growth Strategies in the Human Microbiome Market
11.3 Organic Growth Strategies
- 11.3.1 Overview
11.4 Inorganic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 MaaT Pharma
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Ferring Holdings SA
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 AOBiome Therapeutics Inc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Finch Therapeutics Group Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Financial Overview
- 12.4.4 SWOT Analysis
- 12.4.5 Key Developments
12.5 Seres Therapeutics Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Merck & Co Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Yakult Honsha Co., Ltd.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Rebiotix, Inc.
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 IFF Nutrition & Biosciences
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Synthetic Biologics, Inc.
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 Glossary of Terms
13.2 About The Insight Partners